Nurix Therapeutics
Clinical-stage biopharmaceutical company developing targeted protein degradation therapies using its proprietary DELigase platform to harness the body's protein disposal machinery for treating cancer and immune disorders.
Website
https://www.nurixtx.comLocation
San Francisco, California, USA
Founded
2015
Categories
biotech, targeted-protein-degradation, oncology, immunology
Notes
Nurix Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapies that harness the body's natural protein degradation machinery to treat cancer and immune disorders. The company's proprietary DELigase platform enables the discovery of targeted protein degraders and inhibitors of E3 ligases.
Nurix's approach focuses on using the ubiquitin-proteasome system to degrade disease-causing proteins that were previously considered "undruggable."
Team
- Arthur T. Sands, M.D., Ph.D. - President & Chief Executive Officer
- LinkedIn: linkedin.com/in/arthursands
- Gwenn Hansen, Ph.D. - Chief Scientific Officer
Additional Research Findings
- Founded in 2015 in San Francisco, California
- Listed on NASDAQ (ticker: NRIX)
- Proprietary DELigase platform for targeted protein degradation
- Focus on E3 ligase biology and ubiquitin-proteasome system
- Multiple clinical programs in oncology and immunology
- Strategic collaboration with Sanofi on DELigase technology
- Pioneer in targeted protein degradation field